{"id":"placebo-to-match-solifenacin-succinate","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used in controlled trials to provide a comparison arm against active drug. This particular placebo is manufactured to be indistinguishable from solifenacin succinate (an anticholinergic agent used for overactive bladder) in terms of appearance, taste, and packaging, enabling double-blind study design while the actual therapeutic effect comes from solifenacin's muscarinic M3 receptor antagonism.","oneSentence":"This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:52.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control for solifenacin succinate trials in overactive bladder"}]},"trialDetails":[{"nctId":"NCT01093534","phase":"PHASE4","title":"Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01-19","conditions":"Detrusor Overactivity, Overactive Bladder","enrollment":547},{"nctId":"NCT01371994","phase":"PHASE4","title":"A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-08-02","conditions":"Urinary Incontinence","enrollment":640},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":"Urinary Bladder Overactive, Urinary Bladder Diseases\\Urologic Diseases, Overactive Bladder","enrollment":3527},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":"Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases","enrollment":2174},{"nctId":"NCT01565707","phase":"PHASE3","title":"A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-06-07","conditions":"Urinary Bladder, Overactive","enrollment":189},{"nctId":"NCT02045862","phase":"PHASE3","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-17","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence","enrollment":1829},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":"Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations","enrollment":1307},{"nctId":"NCT05282069","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2022-05-12","conditions":"Overactive Bladder","enrollment":607},{"nctId":"NCT01018264","phase":"PHASE4","title":"Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2010-01","conditions":"Overactive Bladder in Parkinson's Disease","enrollment":23},{"nctId":"NCT03566134","phase":"PHASE2","title":"A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-07-10","conditions":"Overactive Bladder","enrollment":306},{"nctId":"NCT02169713","phase":"PHASE1","title":"Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-05","conditions":"Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)","enrollment":20},{"nctId":"NCT00507455","phase":"PHASE2","title":"Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-06","conditions":"Lower Urinary Tract Symptoms, Bladder Outlet Obstruction","enrollment":222},{"nctId":"NCT00573508","phase":"PHASE4","title":"Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-08","conditions":"Urinary Bladder, Overactive","enrollment":768}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes. Used for Placebo control for solifenacin succinate trials in overactive bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}